Reviews/COPD Pharmacotherapy/Inhaled corticosteroids raise pneumonia risk
Ics Risk · COPD-ICS-01 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
Across several study designs, people with COPD who use inhaled corticosteroids tend to get pneumonia more often than those who do not. A large insurance-database study found the risk fell by about a third after people stopped the drug [2], and a national cohort found the risk climbed as the dose climbed [5], which together point toward the drug itself playing a causal role rather than just marking sicker patients. A matched analysis inside a trial also found more pneumonia with fluticasone than with no inhaled steroid [4]. The signal is clearest for the drug fluticasone and in more severe disease, while one large trial found no extra risk in people with only moderate airflow loss [3] and another found little overall difference except in older patients [7]. The panel treated the overall claim as well supported while noting these limits on exactly who it applies to.
Direct randomised data show radiographically confirmed pneumonia rising with inhaled fluticasone furoate and vilanterol versus vilanterol alone [1]. A matched post hoc of a trial found fluticasone propionate versus no inhaled steroid carried a hazard ratio of 1.33 (95% CI 1.00, 1.75) [4], and a large population cohort found a hazard ratio of 1.62 (95% CI 1.54-1.70) with a monotonic rise across cumulative dose [5]. Reversibility supports a causal reading: stopping inhaled steroids was associated with a 37% fall in serious pneumonia (RR 0.63, 95% CI 0.60-0.66) [2]. The association is strongest for fluticasone and weaker for budesonide, both in the withdrawal data ([2] budesonide RR 0.87, 95% CI 0.78-0.97) and in a head-to-head cohort ([6] fluticasone propionate vs budesonide HR 1.34, 95% CI 1.26-1.43). The contested point: The evidence divides on scope rather than direction: SUMMIT found increased pneumonia risk was not evident in patients with moderate airflow limitation [3], and the IMPACT analysis found little overall differential between inhaled-steroid and non-steroid treatments except in patients over 63 years [7]. It further divides on whether a class statement is warranted, since much of the signal is fluticasone-specific while budesonide is comparatively weak [2][6].
All 11 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from COPD Pharmacotherapy, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The large registry cohorts [2][5][6] are vulnerable to confounding by indication — ICS are prescribed to sicker, exacerbation-prone patients who are independently pneumonia-prone; matching/adjustment reduces but cannot eliminate this.
Outcome indirectness: [1] shows investigator-reported pneumonia (3-7%) substantially overstates radiographically confirmed events (2-5%), so effect sizes from unadjudicated endpoints are inflated.
Where it remains uncertain. No increased risk was seen in moderate airflow limitation [3] and little overall differential outside older patients [7], so an unqualified 'in COPD' overreaches the severity range tested.
Aleatory
Confirmed pneumonia incidences in the trial strand are a few percent (2-5% in [1]), so individual-event randomness limits precision at the margins.
Epistemic
Whether the risk is a class effect or largely fluticasone remains open, with budesonide weaker in [2] (RR 0.87) and [6].
Inferential
Causal attribution rests on cohorts [2][5][6] where inhaled steroids are prescribed to sicker, pneumonia-prone patients; matching reduces but cannot eliminate this.
The load-bearing papers from a corpus of 11, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
RCT with radiographic adjudication confirms an increased, dose-related ICS pneumonia risk.
“Radiographically confirmed pneumonia risk is increased with inhaled FF/VI, although at less than investigator-defined rates.”
Panel auditInternal validity: high · scope of inference: COPD patients with moderate to very severe airflow limitation and at least one exacerbation in the prior year, treated with fluticasone furoate added to vilanterol.Key limitations: contrast is ICS+LABA vs LABA, not ICS vs no treatment · no CI or p value for headline increase · only one ICS molecule (FF)
Reversibility on withdrawal strengthens causal inference beyond confounding by indication.
“Discontinuation of ICSs was associated with a 37% decrease in the rate of serious pneumonia (rate ratio [RR], 0.63; 95% CI, 0.60-0.66).”
Panel auditInternal validity: medium · scope of inference: COPD patients in Quebec treated with ICS between 1990 and 2005, with serious pneumonia defined as hospitalization or death.Key limitations: observational, residual confounding possible · serious pneumonia only (hospitalization/death) · contrast is discontinuation vs continuation, indirect test of the claim
Direct ICS-vs-no-ICS matched contrast within an RCT population.
“A significantly greater risk of pneumonia was observed for FP versus no ICS: the hazard ratio (HR) for risk of pneumonia was 1.33 (95% confidence interval [CI] 1.00, 1.75; p = 0.046)”
Panel auditInternal validity: medium · scope of inference: COPD patients in the UPLIFT trial who were permanent users of fluticasone propionate, other ICS, or no ICS.Key limitations: post hoc, non-randomized ICS allocation · signal driven by fluticasone propionate specifically · CI lower bound at 1.00
Scope limit: null signal in moderate airflow limitation qualifies generalizability.
“increased pneumonia risk with inhaled corticosteroid use was not evident in COPD subjects with moderate airflow limitation and heightened cardiovascular risk.”
Panel auditInternal validity: high · scope of inference: COPD patients with moderate airflow limitation (50% ≤ FEV1 ≤ 70% predicted) and heightened cardiovascular risk.Key limitations: restricted to moderate airflow limitation, not severe disease · no CI or p value for the null comparison · single ICS molecule (FF)
4 of 11 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Multiple independent high-quality designs show a consistent, dose-related and reversible increase in pneumonia risk, held just below the top of the band by severity- and molecule-dependent heterogeneity.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Severity-stratified adjudicated risk. The null in moderate airflow limitation [3] versus the severe-disease signal [1] is unexplained within a single design, and the claim is worded without severity qualification. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A prospective study with radiographically adjudicated pneumonia stratified prospectively by airflow-limitation grade.
Open question: Does budesonide, as opposed to fluticasone, increase pneumonia risk relative to no inhaled corticosteroid in COPD? Why it is still open: The corpus shows budesonide is weaker than fluticasone ([2] RR 0.87; [6] HR 1.34 for fluticasone vs budesonide) but never contrasts budesonide against no inhaled steroid.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19